29,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Delirium was associated with a higher risk of nursing home admission in participants without dementia (SHR 1.23, 95% CI 1.14-1.34) and with pre-existing dementia (SHR 1.22, 95% CI 1.07-1.38). 5 key findings →
Design: cohort study Participants: 13 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) has a strong genetic component, with APOE ε4 being the most established risk factor through its effects on beta-amyloid (Aβ) metabolism and microglial function. 5 key findings →
Participants: 500,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The analytic sample included 1 054 926 beneficiaries, including 219 942 (mean [SD] age, 75.3 [6.3] years; 54.6% female) who developed new complex conditions in 2019 and 834 984 (mean [SD] age, 73.8 [5.6] years; 56.7% female) who did not develop a new complex condition in 2019. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
For VA and Medicare cohorts, dementia diagnosis was absent in 88.7% and 80.5%, respectively, of follow-up encounters in the other system. 5 key findings →
Design: cohort study Participants: 68,092 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Overall, 92.7% of the original cohort members participated in at least one follow-up round and 87.2% participated in at least two (balanced by deworming treatment status). 4 key findings →
Design: longitudinal study Participants: 7,527 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Overall, both algorithms demonstrated comparable performance in MA and FFS populations, with high specificity (>97.9%) and negative predictive value [NPV] (>92.9%). 5 key findings →
Participants: 5,018 Evidence: low
Full summary, score breakdown and related studies → Original source
Research on music therapy for older adults is a rapidly expanding and involves strong global collaboration. 2 key findings →
Participants: 5,253 Evidence: low
Full summary, score breakdown and related studies → Original source
The study cohort included 1 415 265 long-stay nursing home residents with dementia who died between 2013 and 2022. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Secondary outcomes included plan- and county-level factors associated with offering this benefit in 2025, estimated using multivariable mixed-effects logistic regression with county-level random intercepts. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Of the 508 eligible MA enrollees, mean age was 82.8 (SD = 7.2) years, 81% were female, and 49% were non-Latino White; 62 participants (12%) were classified as having dementia by the cohort assessment. 5 key findings →
Design: cohort study Participants: 62 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Additional Roles Reimbursement Scheme (ARRS) launched in England in 2019 to expand the multidisciplinary primary care workforce, but its impact on workload since implementation is unclear. 1 key finding →
Design: cohort study Participants: 986 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among TM enrollees, prevalence of dementia was lower by 4% points in 2014 (9.0%, 95%CI: 7.8%, 9.3%) compared to 2000 (13.0%, 95%CI: 12%, 14%). 5 key findings →
Design: cross-sectional Participants: 18,381 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 6158 person-waves with a claims-based dementia diagnosis from 3278 PWPD (3134 [50.9%] aged 65-84 years; 4282 [69.5%] female; 1176 [19.1%] non-Hispanic Black, 617 [10.0%] Hispanic, and 4256 [69.1%] non-Hispanic White), the adjusted proportion not reporting their diagnosis was 42% (95% CI, 40%-43%) among all respondents and 67% (95% CI, 64%-69%) among self-respondents. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 5353 MA beneficiary observations (1239 [23.1%] aged 65-74 years; 3127 [58.4%] aged ≥75 years; 1785 male [33.3%]), 1629 (30.4%) reported a diagnosis of ADRD, and 3724 (69.6%) did not report an ADRD diagnosis. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In a sample of 1218 new HCBS users (75% female, 77% Black; mean [SD] age, 70.5 [7.5] years), Medicaid HCBS initiation was associated with a decrease in probability of ED use (-2.70 percentage points; 95% CI, -4.18 to -1.22 percentage points) and a decrease in probability of inpatient discharge (-2.63 percentage points; 95% CI, -3.75 to -1.51 percentage points). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Oral health is strongly associated with overall health. 5 key findings →
Design: cross-sectional Participants: 1,488 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's blood-based biomarker (BBM) tests using single biomarkers or ratios are well characterized, but head-to-head comparisons of multi-analyte algorithmic tests on shared cohorts are lacking. 4 key findings →
Design: cross-sectional Participants: 192 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Loneliness, distinct from social isolation, is a subjective sense of social disconnection exacerbating a public health crisis among older adults. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among 421,131 MA beneficiaries, telehealth use increased sharply in Q2 2020 for both ADRD and non-ADRD groups, peaking at 33.9 and 30.6% respectively. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The expert panel from Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia discussed the current situation of various topics related to the diagnostics, general management and treatment of Alzheimer's disease (AD) in these Central Eastern European (CEE) countries, representing around 88 million population. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The simulated cohort was informed by 111 600 PWH enrolled in Medicare at the start of 2026 (mean [SD] age, 70.9 [5.0] years; 77% male). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Structural brain imaging is guideline-recommended for cases with newly diagnosed cognitive impairment. 2 key findings →
Design: cross-sectional Participants: 1,095,947 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
As disease-modifying therapies for Alzheimer's disease become available, ensuring equitable access to timely and accurate diagnosis of cognitive impairment is critical. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease, the leading cause of dementia, is a multifactorial disorder involving amyloid beta (Aβ) and tau deposition, impaired glucose metabolism, neuroinflammation, mitochondrial dysfunction, insulin resistance, and progressive brain atrophy. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We aimed to explore primary care physicians' (PCP) attitudes, perceptions, and barriers toward Alzheimer's disease (AD) diagnosis and incorporating blood biomarker (BBM) tests into the diagnostic workflow. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,380 records, built mostly from automated pulls of Europe PMC (63.3% of the library) and OpenAlex (17.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →